| Reference |
|---|
Ramos A, Koch C, Liu Lupo Y, Hellinger R, Kyung T, Abbott K, et al. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening. Nat Commun. 2023;14:8048 pubmed publisher |
Lee S, Yeom S, Lee J, Park C. Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents. Sci Rep. 2021;11:10145 pubmed publisher |
Gao M, Fu Y, Zhou W, Gui G, Lal B, Li Y, et al. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma. Cancer Res. 2021;81:3580-3592 pubmed publisher |
Fan F, Zhou M, Ye X, Mo Z, Ma Y, Luo L, et al. BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021;14:100961 pubmed publisher |
Hu L, Shen D, Liang D, Shi J, Song C, Jiang K, et al. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth. Cancer Lett. 2020;493:156-166 pubmed publisher |
Fraser J, Simpson J, Fontana R, Kishi Itakura C, Ktistakis N, Gammoh N. Targeting of early endosomes by autophagy facilitates EGFR recycling and signalling. EMBO Rep. 2019;20:e47734 pubmed publisher |
Zebertavage L, Bambina S, Shugart J, Alice A, Zens K, Lauer P, et al. A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity. PLoS ONE. 2019;14:e0209153 pubmed publisher |
Kim D, Park S, Kim D, Jeong M, Noh J, Kwon Y, et al. Direct visualization of single-molecule membrane protein interactions in living cells. PLoS Biol. 2018;16:e2006660 pubmed publisher |
Sirinian C, Papanastasiou A, Schizas M, Spella M, Stathopoulos G, Repanti M, et al. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling. Oncogene. 2018;37:5101-5114 pubmed publisher |
Papanastasiou A, Sirinian C, Plakoula E, Zolota V, Zarkadis I, Kalofonos H. RANK and EGFR in invasive breast carcinoma. Cancer Genet. 2017;216-217:61-66 pubmed publisher |
Mayrhofer M, Gourain V, Reischl M, Affaticati P, Jenett A, Joly J, et al. A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth. Dis Model Mech. 2017;10:15-28 pubmed publisher |
Ma Y, Tang N, Thompson R, Mobley B, Clark S, Sarkaria J, et al. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res. 2016;22:1767-76 pubmed publisher |
Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-61 pubmed publisher |
Li L, Dutra A, Pak E, Labrie J, Gerstein R, Pandolfi P, et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009;11:9-21 pubmed publisher |
